The Science Behind R³ Technology®

Repair · Restore · Reinforce

The Science of R³ Technology®

Repair · Restore · Reinforce

At the heart of the ICONA® Pn range lies R³ Technology® (Repair, Restore, Reinforce) — a proprietary formulation innovation from Gill Pharmaceuticals Ltd, developed to support skin quality and dermal structural integrity using carefully engineered polynucleotide formulations. The polynucleotide component is polydeoxyribonucleotide derived from salmonid DNA, purified to injectable-grade standards. By blending advanced biopolymer science with an understanding of skin structure, this technology provides a smarter, more refined approach to skin quality rejuvenation within the dermal environment.

The result is a next-generation, non-volumising injectable platform designed to work in harmony with the skin’s natural environment, supporting tissue quality and aesthetic vitality over time.

Key Scientific Features of R³ Technology®

Optimized Dermal Bioavailability

R³ Technology® optimises the formulation’s pH and ionic strength to closely align with human tissue, creating an isotonic environment designed to support dermal compatibility and local formulation stability following administration. By maintaining a skin-compatible pH range (approximately 6.8–7.2) and appropriate osmolarity, the polynucleotide components remain stable and available within the dermal environment.

The polynucleotide material is carefully processed to achieve a controlled molecular weight spectrum, balancing shorter nucleotide fragments with longer-chain polynucleotides. This approach is intended to support both early dermal interaction and sustained presence within the dermal matrix, with larger chains remaining locally for longer-term structural support. The polynucleotides are highly purified and free from oxidative contaminants, supporting formulation integrity and stability over time.

  • Prolonged Localised Presence
    By matching physiological conditions, the polynucleotide (PN) components are retained locally at the injection site rather than rapidly dispersing. This allows for a more sustained supportive interaction within the skin and reduced distribution beyond the treated area. The polynucleotides effectively “settle” within the dermal matrix, where they can remain in close association with surrounding tissue structures.
  • Efficient Dermal Availability
    Skin cells (such as fibroblasts) can readily interact with optimally sized PN fragments, supporting skin quality–related processes with minimal dispersion. In practice, this translates to support for collagen-associated structural integrity and oxidative balance within the treated area, without oversaturating the local environment. By maintaining the formulation components concentrated within the dermis, R³ Technology® limits unwanted systemic exposure and focuses skin quality support precisely where it is intended.


Supportive Vascular and Inflammatory Modulation

Polynucleotide components within the formulation are designed to interact with dermal cell populations, including fibroblasts and endothelial-associated structures, supporting pathways associated with tissue conditioning and repair processes. This interaction is associated with the presence of factors involved in vascular support and tissue nourishment, contributing to improved dermal conditions over time.
At the same time, formulation design supports a balanced local tissue response, helping to moderate excessive inflammatory signalling and encourage a more controlled dermal environment. This dual supportive interaction reflects aspects of the skin’s natural response to injury, without provoking excessive irritation or inflammatory stress.

By supporting vascular-associated tissue conditions, R³ Technology® contributes to improved dermal nourishment and overall tissue quality. Enhanced local conditions support oxygen and nutrient availability within the dermal environment, contributing to a healthier setting for ongoing skin quality improvement. Concurrently, the formulation’s tissue-compatible design supports a gentle, well-tolerated response, helping to limit oxidative stress and excessive inflammatory markers during post-treatment recovery. This controlled interaction supports efficient skin quality improvement without the collateral effects or downtime associated with more aggressive inflammatory approaches.

  • Enhanced Local Tissue Support:
    Improved local dermal conditions within the treated area are associated with better tissue nourishment and perfusion, supporting a more favourable environment for skin quality maintenance. In practical terms, fibroblast-associated structures are exposed to improved local conditions, which helps support collagen- and elastin-related structural integrity over time. Enhanced local support can also contribute to a healthier-looking skin appearance and assist in recovery following micro-procedural stress. Over time, this supportive effect contributes to improved dermal quality and visual skin refinement.
  • Gentle Skin Quality Response:
    By supporting a balanced local tissue response, R³ Technology® helps minimise excessive post-treatment redness, swelling, and discomfort. Patients may experience a calmer recovery profile with minimal downtime. Importantly, maintaining a controlled local environment helps limit stress on dermal structures, supporting preservation of collagen-associated matrix components. This means skin quality improvement occurs in an environment conducive to gradual structural support, rather than one dominated by irritation or inflammatory stress. Clinically, this supportive response is associated with smoother skin appearance and improved surface uniformity, contributing to enhanced firmness and elasticity without increasing the risk of unwanted fibrotic or inflammatory reactions.

Nucleotide Support & Dermal Renewal

R³ Technology® provides a local source of nucleotide-related components via its polynucleotide formulation, designed to support dermal structural maintenance and renewal processes. Following administration, the polynucleotide chains are gradually broken down within the dermal environment into smaller nucleotide-related units. These components remain locally available and are utilised by dermal tissue as part of normal structural turnover and maintenance, particularly in skin affected by ageing or environmental stress.

By enriching the dermal environment with readily available formulation components, R³ Technology® supports ongoing skin quality improvement and tissue resilience. Fibroblast-associated structures, in particular, are supported within a favourable dermal environment that contributes to collagen- and elastin-associated structural integrity, as well as overall matrix support. In this context, the polynucleotide formulation acts as a biocompatible structural support within the dermis, complementing natural skin maintenance processes without introducing foreign proteins or reactive substances.

  • Support for Structural Integrity:
    By maintaining a supportive dermal environment, the formulation contributes to improved skin density, firmness, and elasticity over time. As structural components of the dermal matrix are supported, the skin may appear more resilient and refined, with visible improvement in overall skin quality.
  • Comprehensive Skin Quality Support:
    Beyond structural support, this dermal-focused approach contributes to balanced hydration, improved surface texture, and a more even skin appearance. Skin may appear brighter, smoother, and more uniform as part of a gradual skin quality improvement process. By working in harmony with normal dermal maintenance pathways, R³ Technology® supports natural-looking, progressive aesthetic outcomes without reliance on aggressive or inflammatory mechanisms

Skin Biocompatibility and Safety

The R³ Technology® formulation is engineered with a strong focus on biocompatibility and tissue tolerance. It is isotonic and pH-balanced to align with the skin’s natural conditions, supporting a well-tolerated dermal interaction following administration. In addition, the polynucleotides are produced through a controlled purification process designed to remove residual proteins, peptides, and contaminants from the source material. This high level of purification supports a formulation that is well-accepted within the dermal environment.

R³ Technology® contains no chemical cross-linking agents, no parabens, and no permanent gel components. The polynucleotide strands are biodegradable biopolymers, which are gradually broken down within the body into naturally occurring nucleotide components. As the formulation does not contain permanent particles or microspheres, it is designed to integrate smoothly within the dermal environment, supporting a favourable safety and tolerability profile. In line with Gill Pharmaceuticals’ quality standards, each batch undergoes rigorous quality, sterility, and endotoxin testing prior to release for clinical use.

  • Low Incidence of Post-Treatment Reactions:
    Clinical use of the ICONA® PN range is associated with a low incidence of transient post-injection reactions, such as mild erythema or oedema at the injection site. When present, these effects are typically short-lived and comparable to those observed with other non-volumising injectable skin quality treatments. The formulation’s purified, non-animal-derived composition supports a well-tolerated treatment experience.
  • Suitable for Sensitive Skin Types:
    The gentle formulation design of R³ Technology® supports use in sensitive or fragile skin, including areas affected by photoageing or environmental stress. The absence of permanent materials means the formulation does not persist as a foreign substance within the tissue, supporting repeat treatment protocols where clinically appropriate. Overall, the combination of formulation purity, biodegradability, and quality controls contributes to a high level of clinical tolerability across a broad range of aesthetic indications.
  • Contains salmonid-derived polynucleotides. Not suitable for patients with known fish allergy. For professional use only.

Formulated by Science.

Driven by Results.

The result is a non-volumising biorevitalising injectable platform designed to work in harmony with the skin’s natural environment — not against it.
The ICONA® Pn range, powered by R³ Technology®, delivers science-led skin quality improvement with clinical precision and natural elegance. Each product in the range applies this advanced polynucleotide formulation approach to support skin quality, radiance, and overall appearance over time.

ICONA® Pn RANGE

A.R.T. Technology®

Advanced Regenerative Technology

A.R.T. Technology® is ICONA’s advanced formulation system designed to optimise hyaluronic acid performance and cellular compatibility. It focuses on stability, bioavailability, and precision hydration support — helping deliver consistent skin quality improvement through high-purity HA-based injectables.

Used in: ICONA® H1 and ICONA® H8

Explore A.R.T. Technology®

R³ Technology®

Repair · Restore · Reinforce

R³ Technology® is ICONA’s polynucleotide formulation platform, designed to support tissue quality and dermal matrix integrity through a structured formulation approach. It is engineered to deliver progressive, non-volumising skin quality improvement across multiple anatomical zones — including the face, body, eyes, and scalp.

Used in: ICONA® Pn Range (Face, Body, Eyes, Hair)

Explore R³ Technology®